BIO INX: Bridging the Gap Between Regenerative Research and Real-World Impact
BIO INX's co-founder and CEO, Jasper Van Hoorick, was driven by the belief that materials science could be the key to solving challenges in regenerative medicine. His background in polymer chemistry and a PhD focused on corneal regeneration opened his eyes to a repeating pattern in academic research. BIO INX's co-founder and CEO, Jasper Van Hoorick
"Promising materials and prototypes would be developed, never further than academic publications, only to be shelved when the original researchers move on," Van Hoorick shares. Indeed, progress stalls without a reproducible and standardized pipeline for translating these materials into clinical-grade tools. Instead of waiting for innovation to make its way out of the lab, Van Hoorick decided to take action.
Throughout the final stages of his PhD, Van Hoorick started planning BIO INX in earnest. He wrote grant proposals between thesis chapters, secured initial funding, and built a team that began maturing the company's first products while still operating within the academic environment. By the time the company officially spun out, it had already established partnerships and was positioned to take its materials beyond the proof-of-concept phase.
Now, BIO INX is known for developing and offering high-performance, ready-to-use biomaterials for 3D bioprinting and biofabrication. These materials are crafted with reproducibility, scalability, and compatibility with multiple printing technologies in mind. The company has a diverse and adaptable product portfolio that supports various biomedical applications, from tissue regeneration to pharmaceutical screening.
One of BIO INX's unique strengths is its multidisciplinary foundation. Its team, with over two decades of experience in polymer science, bioengineering, and printing technologies, combines academic expertise with an applied mindset. This enables the company to create materials tailored for specific biological purposes and ensure that those materials meet the technical demands of modern bioprinting platforms. Essentially, with solutions that span different material properties, resolution scales, and printing modalities, BIO INX helps remove the technical obstacles that typically delay or derail regenerative projects. A 3D printed scaffold to guide cell growth made out of DEGRES INX, a biodegradable polyester based resin
The Belgium-based company is proud to share that it has been involved in several proof-of-concept projects that illustrate the clinical and scientific potential of its materials. One of them is the Astrocardia, a heart-on-a-chip experiment. The project has focused on modeling cardiovascular aging, a process that naturally takes decades but is dramatically accelerated in space.
By bioprinting miniature cardiac tissues using a novel bioink, BIO INX has contributed to the development of human-derived aging models. These models may eventually support personalized therapies and more predictive drug screening approaches, both on Earth and in space.
BIO INX has also participated in a project on ocular regeneration. Drawing from Van Hoorick's doctoral work on corneal tissue, the company has been tackling the shortage of viable donor tissue for corneal transplants. "Current treatments rely on corneas from human donors, but the supply is insufficient," Van Hoorick says.
BIO INX has been working in collaboration with a clinical partner to develop bioinks that allow for the regeneration of corneal tissue without the need for invasive surgery. Because the eye is uniquely accessible and allows for direct visual monitoring, it presents a promising target for regenerative strategies. The potential to restore vision with personalized, cell-based therapies could represent a meaningful advancement for patients facing corneal blindness.
A third area that has been in development is cartilage and bone regeneration. The InCart-3D initiative has explored how digital light processing (DLP) bioprinting can be combined with next-generation bioinks to rebuild complex skeletal tissues. Treating the cartilage is challenging because it lacks the natural ability to heal. By creating structurally accurate, cell-friendly constructs that can be integrated with underlying bone, BIO INX is contributing to new possibilities in orthopedic repair.
The work builds on promising preclinical studies where regenerated cartilage enabled mobility recovery in animal models. Through this line of development, the company aims to support therapies for joint degradation, spinal conditions, and other structural issues that impact millions worldwide.
The road to clinical application is complex and highly regulated. Efforts like those of BIO INX represent a step toward a more seamless integration between research and patient care. Through its commitment to standardization, investment in enabling technologies, and involvement in proof-of-concept projects, the company continues to support the field's gradual shift from theory to therapy.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Int'l Business Times
a day ago
- Int'l Business Times
Western Aid Cuts Cede Ground To China In Southeast Asia: Study
China is set to expand its influence over Southeast Asia's development as the Trump administration and other Western donors slash aid, a study by an Australian think tank said Sunday. The region is in an "uncertain moment", facing cuts in official development finance from the West as well as "especially punitive" US trade tariffs, the Sydney-based Lowy Institute said. "Declining Western aid risks ceding a greater role to China, though other Asian donors will also gain in importance," it said. Total official development finance to Southeast Asia -- including grants, low-rate loans and other loans -- grew "modestly" to US$29 billion in 2023, the annual report said. But US President Donald Trump has since halted about US$60 billion in development assistance -- most of the United States' overseas aid programme. Seven European countries -- including France and Germany -- and the European Union have announced US$17.2 billion in aid cuts to be implemented between 2025 and 2029, it said. And the United Kingdom has said it is reducing annual aid by US$7.6 billion, redirecting government money towards defence. Based on recent announcements, overall official development finance to Southeast Asia will fall by more than US$2 billion by 2026, the study projected. "These cuts will hit Southeast Asia hard," it said. "Poorer countries and social sector priorities such as health, education, and civil society support that rely on bilateral aid funding are likely to lose out the most." Higher-income countries already capture most of the region's official development finance, said the institute's Southeast Asia Aid Map report. Poorer countries such as East Timor, Cambodia, Laos and Myanmar are being left behind, creating a deepening divide that could undermine long-term stability, equity and resilience, it warned. Despite substantial economic development across most of Southeast Asia, around 86 million people still live on less than US$3.65 a day, it said. "The centre of gravity in Southeast Asia's development finance landscape looks set to drift East, notably to Beijing but also Tokyo and Seoul," the study said. As trade ties with the United States have weakened, Southeast Asian countries' development options could shrink, it said, leaving them with less leverage to negotiate favourable terms with Beijing. "China's relative importance as a development actor in the region will rise as Western development support recedes," it said. Beijing's development finance to the region rose by US$1.6 billion to US$4.9 billion in 2023 -- mostly through big infrastructure projects such as rail links in Indonesia and Malaysia, the report said. At the same time, China's infrastructure commitments to Southeast Asia surged fourfold to almost US$10 billion, largely due to the revival of the Kyaukphyu Deep Sea Port project in Myanmar. By contrast, Western alternative infrastructure projects had failed to materialise in recent years, the study said. "Similarly, Western promises to support the region's clean energy transition have yet to translate into more projects on the ground -- of global concern given coal-dependent Southeast Asia is a major source of rapidly growing carbon emissions." A Chinese-owned oil refinery on Made Island off Kyaukphyu, Myanmar, photographed in 2019. Beijing is financing a deep-sea port project at Kyaukphyu AFP
DW
2 days ago
- DW
US: Trump sings law paving way for dollar-based stablecoins – DW – 07/19/2025
US President Donald Trump has signed a law to create a regulatory regime for US-dollar-based stablecoins. This could see the cryptocurrency coming into regular use. US President Donald Trump signed a law to create a regulatory framework for stablecoins. This could create a way for the US-dollar-based cryptocurrencies to come into regular use for making payments and moving money. The bill, also known as the GENIUS Act (Guiding and Establishing National Innovation for US Stablecoins), passed in the House of Representatives by a vote of 308 to 122 after being approved by the Senate earlier. "The GENIUS Act, they named it after me," Trump said at the bill-signing ceremony at the White House, where a few government officials, lawmakers, and crypto industry leaders were present. "It's good for the dollar and it's good for the country. That's why I backed you at an early stage. And I also did it for the votes," he added, referring to the crypto industry. This law is a huge victory for the crypto industry and its supporters. They have pushed for such a legislation for a long time, to legitimize the use of cryptocurrencies and make banks, retailers and consumers more willing to use them. The industry donated more than $245 million (€210 million) in last year's elections to boost pro-crypto candidates such as Trump. Stablecoins are designed to maintain a constant value, typically at a 1:1 peg to the US dollar. The GENIUS law requires them to be backed by liquid assets. According to CoinGecko, the stablecoin market is valued at more than $260 billion (€223 billion). Under the new law, Standard Chartered bank says it could grow to $2 trillion by 2028. "This groundbreaking technology will buttress the dollar's status as the global reserve currency, expand access to the dollar economy for billions across the globe, and lead to a surge in demand for US Treasuries, which back stablecoins," Treasury Secretary Scott Bessent said in a statement. However, critics say the law should have included stronger anti-money laundering protections and prohibited foreign stablecoin issuers. They are also wary of the growing influence of a sector that is already powerful. "By failing to close known loopholes and protect America's digital dollar infrastructure, Congress has risked making the US financial system a global haven for criminals and adversarial regimes to exploit," Scott Greytak, deputy executive director of Transparency International US said. Trump has signed an executive order to establish a strategic bitcoin reserve in March this year. He partly owns crypto company World Liberty Financial and launched a meme coin called $TRUMP in January.
Int'l Business Times
3 days ago
- Int'l Business Times
BIO INX: Bridging the Gap Between Regenerative Research and Real-World Impact
Decades of scientific discovery in tissue engineering and regenerative medicine have led to breakthroughs. However, the translation of these technologies into clinical therapies hasn't been as immediate as anticipated. BIO INX was founded to address this bottleneck. Its mission is to equip scientists, clinicians, and industry players with the reliable biomaterials they need to bring 3D bio-printing closer to everyday healthcare. BIO INX's co-founder and CEO, Jasper Van Hoorick, was driven by the belief that materials science could be the key to solving challenges in regenerative medicine. His background in polymer chemistry and a PhD focused on corneal regeneration opened his eyes to a repeating pattern in academic research. BIO INX's co-founder and CEO, Jasper Van Hoorick "Promising materials and prototypes would be developed, never further than academic publications, only to be shelved when the original researchers move on," Van Hoorick shares. Indeed, progress stalls without a reproducible and standardized pipeline for translating these materials into clinical-grade tools. Instead of waiting for innovation to make its way out of the lab, Van Hoorick decided to take action. Throughout the final stages of his PhD, Van Hoorick started planning BIO INX in earnest. He wrote grant proposals between thesis chapters, secured initial funding, and built a team that began maturing the company's first products while still operating within the academic environment. By the time the company officially spun out, it had already established partnerships and was positioned to take its materials beyond the proof-of-concept phase. Now, BIO INX is known for developing and offering high-performance, ready-to-use biomaterials for 3D bioprinting and biofabrication. These materials are crafted with reproducibility, scalability, and compatibility with multiple printing technologies in mind. The company has a diverse and adaptable product portfolio that supports various biomedical applications, from tissue regeneration to pharmaceutical screening. One of BIO INX's unique strengths is its multidisciplinary foundation. Its team, with over two decades of experience in polymer science, bioengineering, and printing technologies, combines academic expertise with an applied mindset. This enables the company to create materials tailored for specific biological purposes and ensure that those materials meet the technical demands of modern bioprinting platforms. Essentially, with solutions that span different material properties, resolution scales, and printing modalities, BIO INX helps remove the technical obstacles that typically delay or derail regenerative projects. A 3D printed scaffold to guide cell growth made out of DEGRES INX, a biodegradable polyester based resin The Belgium-based company is proud to share that it has been involved in several proof-of-concept projects that illustrate the clinical and scientific potential of its materials. One of them is the Astrocardia, a heart-on-a-chip experiment. The project has focused on modeling cardiovascular aging, a process that naturally takes decades but is dramatically accelerated in space. By bioprinting miniature cardiac tissues using a novel bioink, BIO INX has contributed to the development of human-derived aging models. These models may eventually support personalized therapies and more predictive drug screening approaches, both on Earth and in space. BIO INX has also participated in a project on ocular regeneration. Drawing from Van Hoorick's doctoral work on corneal tissue, the company has been tackling the shortage of viable donor tissue for corneal transplants. "Current treatments rely on corneas from human donors, but the supply is insufficient," Van Hoorick says. BIO INX has been working in collaboration with a clinical partner to develop bioinks that allow for the regeneration of corneal tissue without the need for invasive surgery. Because the eye is uniquely accessible and allows for direct visual monitoring, it presents a promising target for regenerative strategies. The potential to restore vision with personalized, cell-based therapies could represent a meaningful advancement for patients facing corneal blindness. A third area that has been in development is cartilage and bone regeneration. The InCart-3D initiative has explored how digital light processing (DLP) bioprinting can be combined with next-generation bioinks to rebuild complex skeletal tissues. Treating the cartilage is challenging because it lacks the natural ability to heal. By creating structurally accurate, cell-friendly constructs that can be integrated with underlying bone, BIO INX is contributing to new possibilities in orthopedic repair. The work builds on promising preclinical studies where regenerated cartilage enabled mobility recovery in animal models. Through this line of development, the company aims to support therapies for joint degradation, spinal conditions, and other structural issues that impact millions worldwide. The road to clinical application is complex and highly regulated. Efforts like those of BIO INX represent a step toward a more seamless integration between research and patient care. Through its commitment to standardization, investment in enabling technologies, and involvement in proof-of-concept projects, the company continues to support the field's gradual shift from theory to therapy.
